|
Re: Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
|
8
|
Resverlogix Corp.
|
Aug 05, 2020 12:41PM
|
|
Re: Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
|
6
|
Resverlogix Corp.
|
Aug 07, 2020 11:42AM
|
|
Re: Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
|
2
|
Resverlogix Corp.
|
Sep 30, 2019 10:33AM
|
|
Re: Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
|
1
|
Resverlogix Corp.
|
Aug 01, 2024 12:32PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
3
|
Resverlogix Corp.
|
Mar 26, 2020 09:31AM
|
|
Re: RESVERLOGIX CORP WTS 2021
|
3
|
Resverlogix Corp.
|
May 12, 2021 11:56AM
|
|
Re: Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Dru
|
10
|
Resverlogix Corp.
|
Nov 01, 2021 11:22AM
|
|
Re: Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Dru
|
1
|
Resverlogix Corp.
|
Nov 01, 2021 12:34PM
|
|
Re: Resverlogix Provides Update on BETonMACE Phase 3 Trial
|
3
|
Resverlogix Corp.
|
Sep 16, 2019 09:27AM
|
|
Re: Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
|
7
|
Resverlogix Corp.
|
Aug 23, 2022 07:39AM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
7
|
Resverlogix Corp.
|
Jun 22, 2020 10:50AM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
9
|
Resverlogix Corp.
|
Jun 22, 2020 06:58PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
10
|
Resverlogix Corp.
|
Jun 22, 2020 09:14AM
|
|
Re: Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
4
|
Resverlogix Corp.
|
Nov 02, 2020 04:58PM
|
|
Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
6
|
Resverlogix Corp.
|
Dec 02, 2019 11:26AM
|
|
Re: Revised target market, indications, market potential? ... and some numbers?
|
7
|
Resverlogix Corp.
|
Jun 14, 2020 12:02PM
|
|
Re: Revised target market, indications, market potential? ... and some numbers?
|
4
|
Resverlogix Corp.
|
Jun 14, 2020 12:10PM
|
|
Re: Revised target market, indications, market potential? ... and some numbers?
|
7
|
Resverlogix Corp.
|
Jun 13, 2020 11:47AM
|
|
Re: Round one
|
12
|
Resverlogix Corp.
|
Jan 27, 2022 03:16PM
|
|
Re: Rules of thumb and broken thumbs...
|
5
|
Resverlogix Corp.
|
Sep 29, 2020 10:07AM
|
